The FDA has granted Teva Pharmaceutical Industries approval for a new liquid formulation of its approved lymphoma drug Treanda. The injection is to be used in patients with chronic lymphocytic leukemia and in those with indolent B-cell non-Hodgkin lymphoma whose conditions worsened while or shortly after being treated with a rituximab agent.

Related Summaries